Clinical trials

Recherche d’études cliniques

Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.

Réinitialiser

Études cliniques 643

Étude / NCT ⇅ Molécule ⇅ Maladie ⇅ Phase ⇅ Statut ⇅ Résultat ⇅ Sponsor ⇅ Pays / centres ⇅ Période ⇅ Détail
NCT04478591
WOC — The Wearing-off Phenomenon of Ocrelizumab in Patients With Multip…
WOC — The Wearing-off Phenomenon … SEP À vérifier COMPLETED En attente / non publié Amsterdam UMC, location VUmc Netherlands · Amsterdam UMC, location VUmc, Amsterdam… 2020-05-12 → 2021-05-01 Ouvrir
NCT04676555
TIMIOS — Time and Motion Study for Ocrelizumab and Ofatumumab Administr…
Ocrelizumab SEP À vérifier COMPLETED En attente / non publié Hoffmann-La Roche United States, Australia · Novartis Investigative Sit… 2021-05-11 → 2021-10-21 Ouvrir
NCT05131984
Ocrelizumab Access by Socio-Economic Status
Ocrelizumab SEP À vérifier COMPLETED En attente / non publié Hoffmann-La Roche United States · Brigham and Women's Hospital, Boston,… 2021-11-18 → 2023-07-01 Ouvrir
NCT05528666
Risk Perception in Multiple Sclerosis
Risk Perception in Multiple Scler… SEP À vérifier COMPLETED En attente / non publié Novartis Pharmaceuticals United States · Novartis Investigative Site, East Han… 2021-09-09 → 2021-09-17 Ouvrir
NCT06127095
A Study to Assess New Participant's Perspectives Beyond Clinical Effica…
A Study to Assess New Participant… SEP À vérifier COMPLETED En attente / non publié Biogen United States · Biogen, Cambridge, United States 2023-11-24 → 2024-11-28 Ouvrir
NCT05210621
CONSONANCE EX — LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELI…
Ocrelizumab SEP Phase 3 ACTIVE_NOT_RECRUITING En attente / non publié Hoffmann-La Roche France · Amiens University Hospital, Amiens, France |… 2022-03-08 → 2029-02-24 Ouvrir
NCT07207148
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agoni…
GLP-1 SEP À vérifier RECRUITING En attente / non publié Northwestern University United States · Northwestern Memorial Hospital, Chica… 2025-11-15 → 2028-08-31 Ouvrir
NCT05974839
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With …
Effect of Ocrelizumab on Cortical… SEP À vérifier COMPLETED En attente / non publié State University of New York at B… United States · Buffalo Neuroimaging Analysis Center,… 2023-10-01 → 2024-02-28 Ouvrir
NCT05974852
ORATORIO-CP — Effect of Ocrelizumab on Choroid Plexus Changes in Patien…
ORATORIO-CP — Effect of Ocrelizum… SEP À vérifier COMPLETED En attente / non publié State University of New York at B… United States · Buffalo Neuroimaging Analysis Center,… 2023-10-01 → 2023-12-30 Ouvrir
NCT04293458
ESOGUARDBE1 — Efficacy of EsoGuard on Samples Collected Using EsoCheck …
EsoGuard SEP NA COMPLETED En attente / non publié Lucid Diagnostics, Inc. United States, Spain · Lucid Investigative Site, Chap… 2020-02-28 → 2022-08-22 Ouvrir
NCT04295811
ESOGUARDBE2 — Efficacy of EsoGuard Assay on Esophageal Surface Cells Co…
EsoGuard (lab assay) SEP NA UNKNOWN En attente / non publié Lucid Diagnostics, Inc. United States, Netherlands · Lucid Investigative Site… 2020-06-18 → 2023-12 Ouvrir
NCT07609537
ICLDR-NAR Tria — Imagery Control Therapy and Lucid Dreaming for REM-Rel…
ICLDR-NAR Tria — Imagery Control … SEP NA COMPLETED En attente / non publié Institute of Behavioral Sleep Med… Colombia · Bahavioral Sleep Medicine Institute, Medel… 2024-03-01 → 2025-06-15 Ouvrir
NCT01194570
ORATORIO — A Study of Ocrelizumab in Participants With Primary Progress…
Ocrelizumab SEP Phase 3 COMPLETED En attente / non publié Hoffmann-La Roche United States, Australia, Austria, Belgium, Brazil, B… 2011-03-02 → 2022-12-31 Ouvrir
NCT02471560
TECONGUT — Tecfidera and the Gut Microbiota
dimethyl fumarate SEP Phase 4 COMPLETED En attente / non publié Biogen Norway · Research site, Drammen, Norway | Research si… 2015-11-06 → 2017-06-12 Ouvrir
NCT05051618
METS in MS — Exercise Training for Managing Major Depressive Disorder i…
METS in MS — Exercise Training fo… SEP NA RECRUITING En attente / non publié University of Illinois at Chicago United States · University of Illinois at Chicago, Ch… 2023-04-01 → 2026-10-31 Ouvrir
NCT01617395
Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Su…
Relating Genetic and Environmenta… SEP À vérifier COMPLETED En attente / non publié National Institute of Neurologica… United States · National Institutes of Health Clinica… 2012-08-15 Ouvrir
NCT04062331
Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis
Transcranial Magnetic Stimulation… SEP Phase 1 UNKNOWN En attente / non publié Neuromed IRCCS Non communiqué 2019-10-01 → 2022-10-01 Ouvrir
NCT01714089
Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing R…
RNS60 125 ml SEP Phase 2 WITHDRAWN En attente / non publié Revalesio Corporation United States · Mt. Sinai School of Medicine, New Yor… Non communiqué Ouvrir
NCT04410978
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine …
Tolebrutinib SEP Phase 3 COMPLETED En attente / non publié Sanofi United States, Austria, Belarus, Bulgaria, Canada, Ch… 2020-06-30 → 2024-07-15 Ouvrir
NCT06064539
Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifamp…
Tolebrutinib SEP Phase 1 COMPLETED En attente / non publié Sanofi United States · Prism Research-Site Number:8400001, S… 2020-05-18 → 2020-07-08 Ouvrir
NCT07411924
Mastication, Cognition, and Nutritional Status in Multiple Sclerosis
Mastication, Cognition, and Nutri… SEP À vérifier NOT_YET_RECRUITING En attente / non publié Ondokuz Mayıs University Non communiqué 2026-03-01 → 2026-12-01 Ouvrir
NCT03493841
Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in P…
Alpha Lipoic Acid SEP Phase 1 COMPLETED En attente / non publié Rebecca Spain United States · Oregon Health & Science University, P… 2018-06-08 → 2019-01-25 Ouvrir
NCT04285346
Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term T…
Ganaxolone SEP Phase 2 COMPLETED En attente / non publié Marinus Pharmaceuticals United States · Marinus Research Site, Boston, United… 2020-04-08 → 2022-08-30 Ouvrir
NCT02061397
Safety of Simvastatin in LAM and TSC
Simvastatin SEP Phase 1 COMPLETED En attente / non publié University of Pennsylvania United States · University of Pennsylvania, Philadelp… 2014-03 → 2019-12-13 Ouvrir
NCT05422339
Efficacy of Gamification in Enhancing User Engagement
The MapHabit system (MHS) Alzheimer NA COMPLETED En attente / non publié MapHabit, Inc. United States · MapHabit, Atlanta, United States 2022-09-12 → 2023-12-28 Ouvrir